Navigation Links
YM BioSciences Announces Milestone Payment For Approval Of Nimotuzumab In The Philippines And Indonesia
Date:12/12/2008

ain partnership revenues.

About YM BioSciences

YM BioSciences Inc. is a company that identifies, develops and commercializes differentiated products principally in the area of oncology for patients worldwide. The Company is developing nimotuzumab, a humanized monoclonal antibody, and AeroLEF(R), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. Nimotuzumab is in development targeting multiple tumour types in combination with radiation, chemoradiation and chemotherapy. The drug, which is approved for marketing in a number of countries, is significantly differentiated from all other currently marketed EGFR-targeting agents because of a remarkably benign side-effect profile. In more than 3,000 patients treated worldwide, to date, no Grade III/IV rash or radiation dermatitis has been reported and reports of any of the other side-effects that are typical of EGFR-targeting molecules have been rare. AeroLEF(R) is in development for the treatment of moderate to severe pain, including cancer pain. The product completed a randomized trial in 2007 and is being prepared for late-stage development internationally.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual repo
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
2. Chipscreen Biosciences and HUYA Bioscience Intl Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
3. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
4. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
5. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
6. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
7. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
8. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
9. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
10. Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
11. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 ... the addition of the "Investigation Report on China,s ... Tobramycin is a traditional antibiotic whose eye drop ... the treatment of potential infection or inflammation caused by ... China are able to produce tobramycin, among ...
(Date:8/28/2015)... , Aug. 28, 2015 ... announced the addition of the "Investigation Report ... their offering. Developed by Pharmacia & ... receptor agonist which effectively reduces intraocular pressure. As ... latanoprost (under the trade name of Xalatan) entered ...
(Date:8/28/2015)... , Aug. 28, 2015  Perrigo Company plc ... it has completed the acquisition of leading OTC brands ... €200 million. The transaction is a clear demonstration of ... Company,s leading European distribution network spanning 36 countries.  ... C. Papa commented, "We are excited to complete ...
Breaking Medicine Technology:Investigation Report on China's Tobramycin Market, 2015-2019 2China Latanoprost Market Investigation Report 2015-2019 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4
... management in the biopharmaceutical industry will "redouble efforts at ... intellectual property theft, counterfeiting and piracy, along with real ... a resolution unanimously adopted by the trustees ... the group applauds the ongoing efforts by labor and ...
... Inc. (NASDAQ: IDIX ), announced today that Idenix ... Life Sciences Conference on September 21, 2011 at 2:00 p.m. ... The live and archived webcast of the company ... Idenix Investor Center at www.idenix.com . Please log in ...
Cached Medicine Technology:PILMA Vows to 'Redouble' Support for Increased Protections Against Intellectual Property Theft 2
(Date:8/30/2015)... ... August 30, 2015 , ... ... medical devices for the treatment of prostate cancer, has announced the roll-out of ... at the treatment center in Puerto Vallarta, Mexico. , The Sonablate® technology currently ...
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, 2015, Diane ... Foundation (Meso Foundation) will present an educational program titled “Asbestos and Your Health.” ... through 9:30 PM (doors open at 6:45pm) at Calvary United Methodist Church, 16 E ...
(Date:8/29/2015)... ... ... Dr. Tim Novelli, DC., Founder and President of the Patriot Project, is ... chiropractic field in the military. All too often VA hospitals treat patients with harmful ... to the VA program over a decade ago, the reality is that only 10% ...
(Date:8/29/2015)... ... 29, 2015 , ... People who have heart or lung ... asthma, are at higher risk from wildfire smoke especially in Calgary, Alberta.Those with ... problems (arrhythmia or irregular heartbeat) are also sensitive to air pollution. , ...
(Date:8/28/2015)... ... August 29, 2015 , ... Rio Salado College ... and the student experience as part of the EDUCAUSE - Next Generation Learning Challenges ... , This is the third Breakthrough Models Incubator hosted by EDUCAUSE and ...
Breaking Medicine News(10 mins):Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4
... Test To Provide Physicians in U.S. and Europe ... , MADISON, N.J., June 2 HemoCue AB, an ... subsidiary of Quest Diagnostics Incorporated (NYSE: DGX ), ... Dynamics Corp (MEC) for the exclusive distribution of the Avie(TM) ...
... NEW YORK, June 2 , ... FOI Documents Through 1991 , ... clinical and post-marketing drug,information, has significantly expanded its coverage ... the launch of the FDA Classic,Collection. This collection contains ...
... June 2 Versus Technology, Inc. (Pink Sheets: VSTI) ... and OR Solutions to Chalmers P. Wylie Veterans Ambulatory ... rules-based real-time location information system (RTLiS) will be installed ... surgery center and clinics. , , The ...
... , , , Approval for ... Pa., June 2 B. Braun Medical Inc. (B. Braun), a ... U.S. Food and Drug Administration (FDA) approval for 2g ... DUPLEX(R) Drug Delivery System . , , (Logo: ...
... screens, researchers say , TUESDAY, June 2 (HealthDay News) -- ... more types of cancer than previously thought, a new study ... successfully used for early detection of colorectal cancer, researchers at ... also good at finding other gastrointestinal cancers, such as those ...
... that could influence the way researchers screen for, treat ... cancer, an aggressive form of the disease. One finding ... "Women with locally advanced breast cancer and their ... mass should not be ignored even if someone has ...
Cached Medicine News:Health News:Quest Diagnostics HemoCue AB Subsidiary to Add Avie(TM) Hemoglobin A1c to Diabetes Point-of-Care Test Suite 2Health News:Quest Diagnostics HemoCue AB Subsidiary to Add Avie(TM) Hemoglobin A1c to Diabetes Point-of-Care Test Suite 3Health News:Quest Diagnostics HemoCue AB Subsidiary to Add Avie(TM) Hemoglobin A1c to Diabetes Point-of-Care Test Suite 4Health News:Elsevier's PharmaPendium(TM) Introduces the FDA Classic Collection 2Health News:Elsevier's PharmaPendium(TM) Introduces the FDA Classic Collection 3Health News:Versus Technology, Inc. Announces Sale of Real-Time Location Information System to the Chalmers P. Wylie Veterans Clinic 2Health News:Versus Technology, Inc. Announces Sale of Real-Time Location Information System to the Chalmers P. Wylie Veterans Clinic 3Health News:B. Braun Anticipates Becoming First to Deliver FDA Approved 2g Cefazolin 2Health News:B. Braun Anticipates Becoming First to Deliver FDA Approved 2g Cefazolin 3Health News:Simple Test Could Detect More Gastrointestinal Cancers 2Health News:I-SPY trial offers key insights into locally advanced breast cancer 2Health News:I-SPY trial offers key insights into locally advanced breast cancer 3
... Gentian violet ink stands ... Millimeter scale ruler printed ... for quick measuring. Flexible, ... both inch and metric ...
Freer elevator, double end, 7 1/4", S/B....
Stainless steel dull finish....
The Ultima 2000 SE is flexible in meeting the needs of both office and operating room use. It is the answer for the clinical practice with a wide range of ophthalmic demands looking for minimal risk ...
Medicine Products: